The HIV-associated renal diseases: Current insight into pathogenesis and treatment  by Weiner, Neil J. et al.
Kidney International, Vol. 63 (2003), pp. 1618–1631
PERSPECTIVES IN BASIC SCIENCE
The HIV-associated renal diseases: Current insight into
pathogenesis and treatment
NEIL J. WEINER, JEFFREY W. GOODMAN, and PAUL L. KIMMEL
Division of Renal Diseases and Hypertension, Department of Medicine, The George Washington University Medical Center,
Washington, D.C.
The HIV-associated renal diseases: Current insight into patho- HISTORY
genesis and treatment. Since the description of a new renal A description of a new renal syndrome in patientssyndrome in patients with the acquired immunodeficiency syn-
with what was then only known as the acquired immuno-drome (AIDS) in the middle 1980s, much has been learned
deficiency syndrome (AIDS) was first reported in 1984regarding the association of human immunodeficiency virus
[1, 2]. At the time, HIV had yet to be identified as the(HIV) infection and renal disease. The HIV-associated renal
diseases represent a spectrum of clinical and histopathologic causative agent of AIDS, and it would be years before
conditions. In this review, epidemiologic and clinical aspects the virus was directly implicated in the pathogenesis of
of HIV-associated renal diseases are presented. Particular at- diseases of the kidney. Although there are two estab-
tention is placed on the pathologic and pathophysiologic mech-
lished serotypes of HIV infection, namely HIV-1 andanisms involved in HIV-associated focal glomerulosclerosis,
HIV-2, the term HIV used in this article will signify HIV-1,immune complex–mediated disease, and thrombotic micro-
the predominant virus implicated in human disease in theangiopathies. Pharmaceutical treatment options, including the
use of glucocorticoids, angiotensin-converting enzyme (ACE) United States. In New York City, Rao et al [1] described
inhibitors, and highly active antiretroviral therapy, are dis- focal and segmental glomerulosclerosis in nine patients
cussed. The therapeutic option of renal transplantation is pre- with AIDS and the nephrotic syndrome. The authors
sented, with insight into new clinical and basic research sup- recognized a histologic pattern similar to heroin-associ-
porting a possible role of immunosuppressive therapy in this
ated nephropathy, but noted a much more rapid deterio-already immunocompromised patient population.
ration in renal function in the patients with AIDS. In
Miami, Pardo et al [2] described a variety of glomerular
changes seen at autopsy in 36 patients with AIDS. This
The spectrum of kidney disease among patients in- second report broadened the scope of this new AIDS-
fected with the human immunodeficiency virus (HIV) is associated nephropathy to include mesangial prolifera-
extensive. Acute renal failure (ARF) in patients with tion in addition to glomerulosclerosis. Through the re-
mainder of the 1980s and into the 1990s, it was eventuallyHIV occurs in general for the same reasons as in patients
recognized that HIV infection is associated with a widewithout the viral infection, although some unique causes
range of nephrologic syndromes responsible for bothhave been reported. Cases of chronic renal failure in
acute and chronic renal failure [3–7].patients with HIV, generally termed the HIV-associated
nephropathies, are largely due to focal glomerulosclero-
Acute renal failuresis, immune complex disease, or thrombotic microangio-
ARF in patients infected with HIV occurs primarilypathies. These three syndromes, which are the focus of
for similar reasons as for patients without HIV infection.this review, each have their own epidemiology, clinical
Prerenal causes include hypovolemia due to diarrhea,presentation, pathophysiology, and treatment.
vomiting, and infections; hypotension from sepsis, bleed-
ing, and fluid loss; and hypoalbuminemia due to third-
space fluid loss and cachexia.Key words: HIV, focal glomerulosclerosis, immune complex disease,
Acute tubular necrosis, due to hypovolemia, shock,thrombotic thrombocytopenic purpura, hemolytic uremic syndrome,
renal transplantation, dialysis. sepsis, anoxia, or nephrotoxins, is the most common cause
of intrinsic ARF in patients with HIV infection. Nephro-Received for publication September 27, 2002
toxic agents associated with the development of ARFand in revised form November 7, 2002
Accepted for publication December 17, 2002 include, among those routinely used in the evaluation
and treatment of patients with HIV infection, pentami- 2003 by the International Society of Nephrology
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dine, amphotericin B, foscarnet, aminoglycoside anti- with HIV-FGS in some studies having a history of injec-
biotics, and radiocontrast material. Protease inhibitors have tion drug use [5, 16, 17, 27]. Low socioeconomic status
also been associated with the development of ARF [8–14]. has also been associated with the disease [24].
Other medications, including trimethoprim/sulfameth- HIV-associated ICDs. The HIV-associated ICDs oc-
oxazole, cephalosporins, rifampin, phenytoin, and cimeti- cur much less frequently than HIV-FGS, although some
dine can cause allergic interstitial nephritis. Other etiolo- biopsy series of patients with renal insufficiency, ARF,
gies of intrinsic ARF in HIV-infected patients include or nephrotic syndrome from urban centers on the East
rhabdomyolysis, azotemia from nonsteroidal anti-inflam- Coast of the United States have demonstrated propor-
matory drugs (NSAIDs), postinfectious immune complex tions as high as 25% to 33% [3, 29–34]. In Europe, as
glomerulonephritis, hemolytic uremic syndrome (HUS), seen in case series from London, Paris, and Italy [31, 35,
and thrombotic thrombocytopenic purpura (TTP) [15]. 36], HIV-associated glomerulonephritis appears to be
Postrenal causes of renal failure due to urinary tract more common than HIV-FGS. In addition, Caucasian
outflow obstruction include bladder and urethral ob- patients are noted to represent the majority of individu-
struction; extrinsic compression from tumor, lymph als with such renal diseases. This supports a critical role
nodes, or retroperitoneal fibrosis; and intrinsic obstruc- of host factors in the phenotypic expression of renal
tion from blood clots, fungus balls, or crystalluria. In the disease in HIV-infected patients.
setting of HIV therapy, crystalluria associated with renal Diseases such as membranoproliferative glomerulo-
insufficiency has been associated with indinavir, sulfadia- nephritis, membranous nephropathy, and postinfectious
zine, and acyclovir [10, 15]. glomerulonephritis are often seen in the setting of hepa-
titis B and/or hepatitis C viral infection, and are commonThe chronic HIV nephropathies
in HIV-infected patients with renal disease (especially
Among causes of chronic nephropathy, three syn- those with a history of intravenous drug use). An impor-
dromes have been associated with HIV infection: classic tant question remains in such patients. How directly is
HIV-associated nephropathy with focal glomeruloscle- the pathogenesis of the renal disease associated with the
rosis (HIV-FGS), HIV-associated immune complex re- underlying HIV infection?
nal disease (HIV-ICD), and the thrombotic microangio- Gardenswartz et al [7] reported glomerulonephritis in
pathies, HIV-associated thrombotic thrombocytopenic two of 13 patients with AIDS and proteinuria and/or
purpura/hemolytic uremic syndrome (HIV-TTP/HUS). renal failure. Kimmel et al [30] reported four patients
Each syndrome has its own clinical presentation and with the “classic” clinical presentation of HIV-FGS, but
epidemiologic characteristics that can help the clinician
who were all found to have immune complex disease byto distinguish one from the others.
biopsy.HIV-associated FGS. HIV-FGS is the most common
Nochy et al [31] described four types of glomerulo-of the three HIV-associated nephropathies found in
nephritis in patients with HIV infection in a populationbiopsy series [16–18], although this may be due to higher
of French patients, including some of African heritage:rates of biopsy in patients with the nephrotic syndrome
(1) an immune complex glomerulonephritis, (2) immu-[18, 19]. This syndrome has been reported in all stages
noglobulin A (IgA) nephropathy, (3) a lupus-like syn-of HIV infection, including during acute seroconversion
drome, and (4) a mixed sclerotic/inflammatory pattern[3, 4, 20]. HIV-FGS typically presents with the nephrotic
combining elements of HIV-FGS and proliferative glo-syndrome (often with massive proteinuria of greater than
merulonephritis. In our studies [30], comparison of con-10 g/day), hypoalbuminemia, large, echogenic kidneys
centrations of circulating HIV antigen-antibody immuneby renal ultrasound, and focal and segmental glomerulo-
complexes and elution of immunoreactants from renalsclerosis on renal biopsy. If left untreated, patients with
biopsy tissue were consistent with an immune complexHIV-FGS may rapidly progress to end-stage renal dis-
deposition mechanism of the development of glomerulo-ease (ESRD) in a matter of weeks to months. Peripheral
nephritis. The pathologic findings, however, are also con-edema, hypertension, and hematuria are often absent,
sistent with in situ immune complex–mediated mecha-but may be seen [3, 4, 16, 18, 21–23].
nisms of disease pathogenesis [29, 30], secondary eitherMost patients with HIV-FGS in the United States are
to neoantigen formation or planted antigens, or a sys-young, African American men, although the disease can
temic response to renal infection with HIV. Clinicalbe found in patients from all risk groups for infection with
pathologic analyses cannot in general distinguish be-HIV [3, 4, 16, 17, 24–26]. HIV-FGS is the third leading
tween these two mechanisms of disease pathogenesis.cause of ESRD in the United States among African Amer-
In addition, glomerular inflammatory renal diseaseican males between the ages of 20 and 64 [26–28]. Rates
may be unrelated to the HIV infection, may be influ-of HIV-FGS among African Americans are elevated out
enced by the abnormal immune responses associatedof proportion to the already high rates of HIV infection
with the viral infection, or may be secondary to responsesin this population. There is an association of HIV-FGS
with intravenous drug use, with nearly half of patients to superinfections [29, 30]. Because of limited biopsy
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studies, lack of longitudinal follow-up in the majority tochemical staining and electron-microscopy, is neces-
sary to make a definitive diagnosis of the renal disease.of cases, the potential for bias in sample selection and
because of changes in clinical practices related to antiret-
roviral therapies, any potential differences in the progno-
PATHOLOGY
sis of HIV immune–mediated glomerulonephritides and
HIV-associated FGSHIV-FGS are largely unknown.
The clinical presentation of the immune complex dis- HIV-associated FGS involves all compartments of the
kidney [1, 3, 4, 16, 17, 22, 26, 34, 48–51]. The disease iseases may, however, be very different than that of HIV-
FGS. For example, patients with IgA nephropathy pres- characterized by focal and segmental glomerulosclerosis
associated with microcystic tubular disease in multipleent with hematuria and proteinuria, but often do not
fit the definition for nephrotic syndrome, with 24-hour nephron segments and an interstitial inflammatory cellu-
lar infiltrate [1, 3, 16, 25, 34, 48–51]. The microcysticprotein excretions in the range of 1 to 3 g [30]. These
patients also have a much more indolent course than tubular changes and interstitial edema cause an increase
in kidney size [16, 51]. There is visceral epithelial cellthose with HIV-FGS, and are less likely to progress to
ESRD. Further characterization of differences in out- hypertrophy and “pseudocrescent” formation in Bow-
man’s space. A collapsing variant with shrunken glomer-comes awaits the performance of well-designed studies
with patients categorized by biopsy. uli, wrinkling of the basement membrane, and a marked
increase in Bowman’s space is often seen in associationThrombotic microangiopathies associated with HIV in-
fection. TTP and HUS are related disorders of unknown with glomerulosclerosis and tubular disease [25, 49, 51–53].
Glomerular capillary lumina are often obliterated, andcause that may be different forms of a single clinical
entity. TTP/HUS is characterized by microangiopathic may contain foam cells [51]. Tubules exhibit atrophy and
microcystic dilation, and usually contain proteinaceoushemolytic anemia and renal insufficiency along with
other features, such as thrombocytopenia, fever, and material. A marked tubulointerstitial infiltrate, composed
mostly of T lymphocytes and macrophages [49, 51, 54,neurologic changes. Over the last few years there has
been an increasing number of reports in the literature 55], is a hallmark of the disease and is a striking finding
in the setting of peripheral T cell depletion. Interstitialof TTP/HUS in the setting of HIV infection [37–44].
TTP historically has less extensive renal failure and ane- edema and fibrosis are present.
Immunofluorescence frequently shows staining formia, and thrombocytopenia is most prominent. In con-
trast, in HUS, microangiopathic hemolytic anemia pre- IgM, C3, and, less commonly, C1q; this is usually seen
in areas of glomerulosclerosis and in the mesangiumdominates, and renal dysfunction may be extensive [43].
However, distinctions between these two presentations of nonsclerosed glomeruli [34, 55]. Electron microscopy
demonstrates visceral cell hypertrophy, microvillous trans-may be somewhat arbitrary [43]. The prevalence of HIV
infection among patients with TTP or HUS varies greatly, formation, and profound effacement of foot processes
in both sclerosed and nonsclerosed segments [34].but may be substantial in certain areas of the world,
ranging up to 36% [43]. A recent French retrospective Greater than 90% of renal biopsies of HIV-associated
FGS contain tubuloreticular inclusions (TRIs) within thestudy with biopsy-determined diagnoses by Peraldi et al
[19] suggested that HIV-TTP/HUS may be much more cytoplasm of glomerular and other vascular endothelial
cells [34, 48, 51]. Such inclusions can be induced in vitroprevalent than was previously thought.
The clinical presentation of HIV-TTP/HUS is similar in normal lymphocytes by exposure to interferon-
(INF-) [56].to the idiopathic forms of the disease, although the demo-
graphics differ. HIV-TTP/HUS is a disease of young When compared to uninfected patients with collaps-
ing glomerulopathy, HIV-infected patients demonstratemen, with an 80% male predominance, and a mean age
of onset of 35 years [43]. It is also more common in more frequent TRIs and microcystic tubular histologic
changes [25].Caucasians than in African Americans or Hispanics [43].
Renal insufficiency is usually mild to moderate with the
HIV-associated ICDsserum creatinine often in the range of 2 to 5 mg/dL, and
24-hour protein excretion may be in the nephrotic range There are three distinct HIV-associated glomerulo-
nephritides: (1) a proliferative glomerulonephritis, (2)[45, 46]. Despite similar clinical presentations, however,
the prognosis for patients with HIV-TTP/HUS is signifi- a mixed sclerotic-immune complex nephropathy, and (3)
IgA nephropathy [29, 31]. Fibrocellular crescent forma-cantly worse than for patients with the idiopathic form
of the disease, with mortality rates of 66% to 100% [47]. tion, prominent glomerular visceral epithelial cells, and
microcystic tubular dilation and atrophy are occasionallyThe HIV-associated nephropathies, therefore, are three
distinct syndromes that share many clinical and epidemio- seen. The interstitial infiltrate, in contrast to HIV-FGS,
is composed mostly of B lymphocytes [54]. In additionlogic characteristics. While much can be learned from a
patient’s clinical presentation, a biopsy, with immunohis- to the diffuse proliferative exudative form, a lupus-like
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histology with characteristic “wire loops,” hyaline thrombi gag-pol–deleted HIV-1 transgene, develop renal disease
plugging capillary lumina, and deposits of immunoglobu- similar to HIV-associated FGS in humans [69]. When
lin, C3, and C1q in the mesangium, intracapillary region, these mice are bred onto various other genetic back-
and subepithelial space has been described [29–31, 34, 36]. grounds, the phenotypic expression varies greatly. Spe-
Immunofluorescence demonstrates deposits of immu- cific genes, such as nef, have been shown to influence
noglobulins (IgA, IgM, IgG) and complement (C3, C4, the appearance of tubulointerstitial disease in transgenic
C1q) within the mesangium [57]. Electron microscopy mice with a gag-pol-nef–deleted HIV-1 genome [70].
often reveals subendothelial, intramembranous, and mes-
HIV-associated FGSangial electron-dense deposits. Foot processes are approx-
imated and TRIs may be found in endothelial cells [30]. The pathogenesis of HIV-associated FGS is currently
The pathology of HIV-associated IgA nephropathy unknown. However, increasing evidence suggests that
shows diffuse or segmental mesangial matrix expansion direct viral infection of renal cells by HIV-1 is responsi-
with proliferative changes. Occasionally, fibrocellular ble for the disease [16, 18, 26, 67, 71–74]. Kimmel et
crescent formations are seen [58, 60, 61]. Immunofluo- al [18], using microdissected tissue from renal biopsies,
rescence primarily demonstrates staining for IgA, along identified HIV DNA by polymerase chain reaction
with combinations of lesser amounts of IgM, C3, C1q, (PCR) in glomerular cells, tubular cells, and infiltrating
and less often IgG [58]. Electron microscopy shows thick- leukocytes in HIV-infected patients with nephrotic range
ened foot processes, expansion of the mesangial matrix, proteinuria. Bruggeman et al [71], in a study of biopsies
and mesangial and peripheral intramembranous and/or from 21 HIV-infected patients with kidney disease, de-
subepithelial electron-dense deposits. TRIs may be seen tected HIV-1 mRNA and DNA in renal glomerular and
in glomerular endothelial cells [57–59]. tubular epithelial cells. In addition, circularized viral
DNA, a marker of recent nuclear import of reverse tran-
Thrombotic microangiopathies associated with scribed RNA, was detected by use of PCR techniques
HIV infection in kidney biopsy material.
The pathology of HIV-TTP/HUS is similar to that Apoptosis, or programmed cell death, has been impli-
seen in uninfected patients [42–45, 50, 62]. Platelet and cated in the pathophysiology of HIV-related renal dis-
fibrin thrombi are seen in glomerular capillaries, renal ease [44, 72, 75–78]. Comparing renal biopsy tissue from
arterioles, and interlobular arteries. Arteriolar intimal eight patients with HIV-FGS to 10 patients with idio-
edema, endothelial cell edema, fibrinoid necrosis, mesan- pathic FGS, Bodi, Abraham, and Kimmel [75] detected
giolysis, and “onion skin” lesions may be present [42–45, a significantly higher number of apoptotic tubular cells
50, 62]. Immunofluorescence reveals fibrin and fibrino- in the HIV-FGS specimens. Singhal et al [76] found an
gen in arterioles, in addition to glomerular deposition of increased rate of apoptosis in mesangial cells derived
fibrinogen, C1q, C3, C4, IgA, IgM, and kappa and from HIV-1 transgenic mice when compared to non-
lambda light chains [43]. Electron microscopy may reveal transgenic controls. The effect appeared to be mediated
TRIs in vascular endothelial cells. by tumor necrosis factor- (TNF-). The same group
demonstrated an effect of HIV-1 gp160 protein to stimu-
late murine mesangial cell proliferation in vitro [77].PATHOGENESIS AND PATHOPHYSIOLOGY
Conaldi et al [72], using primary cultures of mesangialThe pathogenesis of renal diseases associated with
and proximal tubular epithelial (PTE) cells from surgi-HIV infection is not completely understood. The host
cally removed kidneys of six HIV-infected Caucasianresponse to chronic HIV infection may include contin-
patients, found HIV-specific receptors and coreceptorsued antibody production, abnormal cell-mediated im-
that permit viral infection. HIV-1 infection triggered anmune responses, and antiviral responses, which may de-
apoptotic pathway involving caspase activation, thus im-termine renal pathologic outcomes [16, 26, 29, 57].
plicating apoptosis as a potential mediator of pathogene-Growth factors, along with the release of proinflamma-
sis. The authors were able to abrogate apoptosis of PTEtory cytokines by HIV-infected lymphocytes and/or renal
cells by inhibiting caspase (despite persistent viral repli-cells, may play a vital role in mediating renal injury [16,
cation).17, 29, 34, 57, 63–67].
In different studies, Conaldi et al [67] detected HIVA genetic component may explain the racial predilec-
replication in mesangial cell cultures. HIV infection stim-tion seen in several HIV-associated renal syndromes.
ulated mesangial cells to express platelet-derived growthFreedman et al [68] identified familial clustering of ne-
factor (PDGF) and transforming growth factor-betaphropathy in uninfected relatives of index patients with
(TGF-), two crucial mediators of glomerulopathy. Fur-HIV infection and renal disease. In addition, studies
thermore, CD4 and chemokine coreceptors CXCR4 andinvolving the HIV transgenic mouse have provided valu-
CCR5 were found on mesangial cell membranes. Usingable insight into the genetic determinants of HIV-associ-
ated renal diseases. Mice of the TG26 line, bearing a PCR techniques, the authors were able to demonstrate
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the expression of HIV mRNA in mesangial cells. An highly active antiretroviral therapy (HAART) and in
increase in cytokine production [interleukin-6 (IL-6), association with a decrease in the serum creatinine con-
TNF-, and IL-8] was observed as early as 3 days follow- centration to 1.4 mg/dL (124 mol/L), was found to have
ing infection. Using inhibitors of cyclin-dependent ki- HIV-1 RNA in tubular epithelial cells and glomerular
nase-9 (flavopiridol and roscovitine), Nelson et al [79] podocytes by in situ hybridization techniques. In addi-
suppressed HIV-1 transcription in transgenic mouse po- tion, the number of renal epithelial cells that expressed
docytes, resulting in their decreased proliferation. This viral mRNA was similar before and during treatment.
evidence supports the pathologic role of HIV infection These results suggest that renal epithelial cells may act
in the up-regulation of renal cytokine gene transcription as a reservoir of HIV-1 RNA transcription in patients
and renal cell proliferation. with HIV-FGS.
The fibrogenic cytokine TGF- has been implicated
in the pathogenesis of HIV-FGS [63, 80, 81]. TGF- HIV-associated ICDs
induces extracellular matrix deposition via several po-
Deposition of circulating immune complexes (CICs)tential mechanisms, including stimulation of matrix syn-
within the kidney may play an important role in thethesis, inhibition of matrix degradation, and alteration
development of HIV-associated glomerulonephritis. Im-of matrix receptors [82]. Bodi et al [80] offered evidence
munoglobulins (IgG, IgM, IgA) may bind circulatingof the important role of TGF- in HIV-associated renal
HIV antigens (p24, gp41, and gp120), resulting in forma-disease. Studying 71 samples of renal tissue from patients
tion of CICs. Such CICs are capable of forming duringwith and without HIV infection, the authors were able
all stages of HIV infection [29]. Kimmel et al [30] de-to correlate the degree of TGF- expression with the
amount of fibrosis present upon histologic examination. scribed four patients with HIV infection, proteinuria and
Furthermore, TGF- levels in HIV-FGS samples were biopsy-proven glomerulonephritis. Various CICs (IgA-
higher by immunostaining when compared to FGS in p24 HIV antigen complex, IgG-gp120 HIV antigen com-
HIV-uninfected patients [80]. In another study, TGF-, plex, IgG-p24 HIV antigen complex) were detected. In
in a dose-dependent manner, was found to increase HIV-1 three out of the four patients, identical complexes were
LTR gene expression in human mesangial cells [63]. found in renal tissue elution studies. The authors pro-
IFNs may play an important role in the pathogenesis posed two potential pathophysiologic mechanisms: (1)
of HIV-associated nephropathy. Tubular reticular struc- deposition of immune complexes acting as the inciting
tures are characteristic of HIV-associated FGS [34, 48, factor; or (2) in situ immune complex formation initiated
57], and are induced in cells in vitro by IFN- [56, 83]. by the presence of HIV genome in renal tissue (Fig. 1).
Phillips et al [84, 85] showed increased IFN- levels in
Cellular immune factors may also play an importantrenal glomerular and interstitial tissue from patients with
role in the expression of renal disease. In both HIV-HIV-associated FGS compared with idiopathic FGS and
associated FGS and HIV-associated ICD, a dense inter-control tissue. Dysregulation of such growth factors and
stitial infiltrate is commonly seen [1, 3, 34, 48–50, 54,cytokine release may predispose to the development of
57]. However, different immune cell populations charac-fibrosis and sclerosis.
terize these two renal diseases, suggesting a cellular in-Recent evidence emphasizes that renal disease can
fluence on phenotypic expression.occur at any stage of HIV infection. Winston et al [20]
IgA nephropathy has been seen in several patientsdescribed a 35-year-old man who had negative serologic
tests for HIV-1 four months prior, but who was admitted with HIV infection [50, 58–60, 62, 87, 88]. The majority of
with a serum creatinine concentration of 1.9 mg/dL, a patients are Caucasian or Hispanic males. IgA antibodies
plasma HIV-1 RNA level 750,000 copies/mL, and a directed against HIV antigens are part of the early immu-
CD4 count of 459 cells/mm3. Urinary protein excretion nologic response to HIV infection [89]. CICs containing
was 17 g/day. The patient’s serum creatinine concentra- IgA are frequently seen in HIV-infected individuals [89].
tion rose to 3.8 mg/dL following admission. Renal biopsy A European biopsy study demonstrated a 7.75% preva-
was consistent with HIV-associated FGS. Levin et al [86] lence of diffuse mesangial deposits of IgA in patients
described HIV-associated nephropathy in a patient with who died of AIDS [87]. Kimmel et al [58] described two
the acute retroviral syndrome.
HIV-infected patients with IgA nephropathy who hadIt has been shown that despite undetectable levels of
CICs containing idiotypic IgA antibody reactive withviremia, HIV-1 may be present in the kidney. Brugge-
IgG or IgM antibodies directed against HIV peptidesman et al [71] reported evidence of viral replication in
(p24, gp120). A similar idiotypic IgA antibody was foundrenal glomerular and tubular epithelial cells in the kid-
in eluates of renal biopsy tissue [58]. This idiotypic im-neys of patients with undetectable viral burden (lower
mune reaction suggests an immunoregulatory dysfunc-limit of detection was 50 copies/mL). Similar findings
tion associated with HIV infection, culminating in renalwere reported by Winston et al [20]. Their patient, de-
spite an undetectable viral burden during treatment with disease.
Weiner et al: The HIV-associated renal diseases 1623
Fig. 1. Human immunodeficiency virus (HIV)-
associated immune complex-mediated renal
disease (HIV-ICD). Primary HIV-1 infection
in patients with specific genetic susceptibilities
leads to synthesis of HIV-1 proteins. HIV-1
directly infects renal cells and HIV proteins
and peptides (some of which are illustrated in
the diagram as examples) may stimulate local
cellular immune responses. Alternatively, cir-
culating immunoglobulins (IgG, IgM, IgA)
may react with HIV-1 proteins, forming circu-
lating immune complexes (CICs), which de-
posit in renal tissue. A cellular immune re-
sponse, potentially influenced by host genetic
factors, may lead to production of cytokines,
growth factors, chemokines, and adhesion
molecules. Such a response may lead to vari-
ous combinations of inflammatory, sclerotic/
fibrotic, and apoptotic responses [see text for
details].
Thrombotic microangiopathies associated with gen activator and basic fibroblast growth factor has been
implicated in the pathogenesis of this disease [94, 95].HIV infection
The role of HIV-1 in the pathogenesis of HIV-associ-The pathogenesis of HIV-associated TTP/HUS is un-
ated TTP/HUS remains unclear. HIV-1 p24 antigen hasknown. The disease is thought to be a result of endothe-
been detected in endothelial cells within the spleen in alial cell injury and platelet deposition within the micro-
patient with thrombotic microangiopathy [96]. The p24vasculature [44, 90]. Coexisting infections, cytotoxins,
antigen, in patients without TTP/HUS, has been found
deficiencies of inhibitors of platelet aggregation, and co-
in endothelial cells within the brain and bone marrow,
agulation cascade abnormalities have all been implicated two organ systems frequently affected in TTP/HUS [42].
in the pathogenesis of the thrombotic microangiopathies In an experimental model using 27 pigtailed macaques
[42, 43, 91–93]. It has been suggested that cytotoxic HIV (Macaca nemestrina) [92] infected with an intravenous
proteins may induce apoptosis of endothelial cells via infusion of a virulent HIV-2 strain, 22% developed histo-
expression of the apoptotic molecule Fas (CD95) [91]. logic evidence of thrombotic microangiopathy. However,
Susceptibility to Fas-induced apoptosis varies; however, the authors suggested that direct HIV-2 infectivity played
the small vessels in the dermis, kidney, and cerebrum no role in the pathogenesis because of the extremely
have been shown to be particularly vulnerable [91]. In rapid course of disease onset and the absence of HIV-2
RNA (in situ hybridization technique) within the kidneyaddition, increased expression of tissue-type plasmino-
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specimens in 98% of the macaques [92]. Despite the talization in patients treated with steroids. In regression
uncertainty regarding the direct role played by HIV-1 in analyses, however, there was no simultaneous control
TTP/HUS, it appears that HIV-1–mediated endothelial for the effect of treatment with angiotensin-converting
damage is important in its pathogenesis. HIV infection enzyme (ACE) inhibitors or perhaps, more importantly,
promotes secretion of inflammatory cytokines, such as for use or type of antiretroviral therapy. Another case
TNF- and IL-1 [42], which, in turn, increases the ex- report [103] suggested that improvement in renal func-
pression of adhesion molecules [vascular cell adhesion tion with the use of glucocorticoids was associated with
molecule-1 (VCAM-1), intracellular adhesion molecule-1 a reduction in lymphocytes and macrophages infiltrating
(ICAM-1), and E selectin] [97, 98]. This series of events the interstitium in a patient with a variant of HIV-FGS.
is followed by endothelial cell retraction and detachment Case reports have described varying clinical outcomes
[97]. in HIV-infected patients with renal disease treated with
New evidence suggests that a deficiency in von Wille- glucocorticoids, ranging from patients recovering renal
brand factor–cleaving protease activity may promote for- function and discontinuing hemodialysis to those suffer-
mation of intra-arterial platelet aggregation, leading to ing serious complications, such as Mycobacterium avium
a thrombotic microangiopathy and end-organ damage intracellulare, Pseudomonas pneumoniae, and cytomega-
in HIV-uninfected patients [99, 100]. Complete defi- lovirus retinal infections [101–106].
ciency of this cleaving protease has been described in ACE inhibitors have been shown to be beneficial in
HIV-associated TTP [99]. patients with HIV-FGS [107, 108]. Kimmel, Mishkin, and
Umana [107], in a nonrandomized, case-control study,
demonstrated the effect of captopril on prolonging theTREATMENT
length of time before death or initiation of renal replace-HIV-associated FGS
ment therapy in nine patients with HIV-FGS matched
The medical literature suffers from a lack of random- by age, race, gender, CD4 count, and serum creatinine
ized, controlled trials aimed at defining the benefits of concentration compared with nine patients with HIV-
any form of therapy for HIV-FGS. While the medical FGS not treated with an ACE inhibitor. Patients in-
community continues to search for the optimal approach, cluded in this study had advanced renal insufficiency
it is reasonable to direct treatment toward the goals of (initial serum creatinine concentrations of 3.4  0.7
reducing HIV-1 replication, slowing the progression of
mg/dL versus 3.7  0.5 mg/dL in the study and control
renal disease, and when necessary, preparing for ESRD
groups, respectively). Renal survival was significantly im-therapy.
proved in the captopril-treated group (156  71 days)The use of corticosteroids in patients with HIV-FGS
versus the control group (37  5 days). In this report,remains a topic of intense debate. Given the paucity
the use of antiretroviral therapy was also significantlyof randomized, controlled trials, it is difficult to form
associated with improved outcome. Burns et al [108], inconclusions regarding their use in this renal disease.
a nonrandomized study, examined the effect of fosinoprilSmith et al [101] reported a reduction in proteinuria and
in patients with less advanced renal insufficiency (initialserum creatinine concentration in patients with HIV-
serum creatinine concentrations of 1.3  0.24 mg/dLFGS (17 of whom were biopsy-proven, three of whom
versus 1.0  0.25 mg/dL in the study and control groups,were presumed to have the disease). The patients were
respectively). Patients who declined treatment with fosi-treated with a tapering prednisone regimen, beginning
nopril were placed in the control group. At 24 weeks,with 60 mg/day, for a 2- to 11-week course. Seventeen
daily urinary protein excretion was 1.25  0.86 g in theof the 20 patients had improvement in serum creatinine
study group, versus 8.5  1.4 g in the control group.concentration, while 12 of the 13 patients demonstrated
Serum creatinine concentrations at 24 weeks were 1.5 reduction in urinary protein excretion. The median time
0.34 mg/dL in the study group versus 4.9  2.4 mg/dLto reach a nadir of serum creatinine concentration was
in the control group. In a study involving the HIV-trans-5 weeks. Complications, including new opportunistic in-
genic mouse [109], treatment with captopril increasedfections, psychosis, and gastrointestinal bleeding, were
survival, improved renal function and histology, and de-relatively common. Eustace et al [102], in a more recent
creased proteinuria. A reduction in glomerulosclerosisretrospective review of 21 patients with advanced, biopsy-
and tubulointerstitial disease was observed. In clinicalproven HIV-FGS, found a beneficial effect of corticoste-
practice, it is important to monitor patients treated withroid therapy. In patients who were treated with 60 mg
ACE inhibitors for the development of hyperkalemiaprednisone daily for 1 month, followed by a gradual
and deterioration of renal function in patients with exist-taper over 2 to 4 months, proteinuria decreased by an
ing renal dysfunction and presumptive HIV-FGS. Weaverage of 5.5 g/day. Furthermore, 23% of the patients
believe that a randomized, controlled study comparingtreated with corticosteroids maintained renal function
the use of HAART versus the use of HAART combinedwithout the need for renal replacement therapy beyond
1 year of follow-up. There was a longer duration of hospi- with ACE inhibitors is warranted.
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Evaluation of the true effectiveness of ACE inhibitor ment with HAART, suggesting a persistent renal reser-
voir of viral transcription.treatment in HIV-FGS depends on the performance of
There are currently no well-controlled studies demon-randomized controlled clinical trials taking into account
strating the effect of long-term HAART on patient out-baseline patient characteristics and treatment parame-
comes.ters. The direct mechanism of action of ACE inhibitors
in this disease is currently unknown, but much specula-
HIV-associated ICDstion has focused on a number of potential actions, includ-
There is a paucity of studies of treatment in patientsing a hemodynamic effect, a reduction in transglomerular
with HIV-associated ICD. Sporadic case reports describ-passage of serum proteins, and effects due to inhibition
ing improvement in renal function with the use ofof TGF-. In addition, it has been noted that serum
HAART, ACE inhibitors, or glucocorticoids have beenACE levels are elevated in HIV-infected patients [110].
published [88, 112, 113]. While the role of glucocorticoidsRecent case reports suggest the potential for dramatic
in the treatment of other types of immune complex–improvement in both renal function and structure in
mediated renal disease has been established, we mustpatients with HIV-FGS with the use of HAART. Wali
assume caution in treating patients with immune com-et al [111], in a case report from Baltimore, Maryland,
plex renal disease and HIV infection with immunosup-described a 37-year-old HIV-infected African American
pressive medications.male with ARF and nephrotic-range proteinuria (9.9
g/day). Within 2 weeks of admission, the patient’s serum Thrombotic microangiopathies associated with
creatinine concentration increased from 2.3 to 5.1 mg/dL. HIV infection
The patient required hemodialysis. His CD4 count was HIV-infected patients who develop TTP/HUS have a
0.04 109/L and the viral load900,000 copies/mL. The poor prognosis. Approximately one third of patients die
prehemodialysis renal biopsy demonstrated HIV-FGS in the acute setting of the illness, despite aggressive treat-
with greater than 70% of the glomeruli exhibiting pseu- ment regimens [43, 93]. The mainstays of therapy include
docrescent formation. HAART (20 mg/day stavudine, both plasma infusion and plasmapheresis, in addition to
50 mg/day lamivudine, and 1250 mg twice a day of nelfi- the treatment of the underlying viral infection. Various
navir) was begun 1 week prior to the initiation of hemodi- other therapies, including antiplatelet agents, vincristine,
alysis. Following roughly 3 months of therapy (including glucocorticoids, and Ig infusions have been used with
hemodialytic support), proteinuria decreased to 700 variable success [42, 43, 93, 114, 115]. Splenectomy has
mg/day and dialysis was discontinued. Renal biopsy per- traditionally been reserved for patients who have refrac-
formed at that time showed almost complete reversal of tory disease following aggressive conventional therapy.
histologic changes. Approximately 3 months later, his Although reports describing a beneficial effect with anti-
serum creatinine concentration was 1.5 mg/dL. Serum retroviral therapy have appeared [116], well-controlled
HIV-RNA was less than 500 copies/mL. In another pa- studies are needed. Despite reported remissions in af-
tient [86], two HIV serologic tests, over a period of 3 fected patients, relapses are common. The relationship
months, were negative. His CD4 count was greater than to the stage of HIV infection is unclear.
500 cells/mm3 and his plasma viral load was 700,000
copies/mL. The enzyme-linked immunosorbent assay TREATMENT OF HIV-INFECTED PATIENTS
(ELISA) and Western blot analyses for HIV antibody AFTER THE DEVELOPMENT OF ESRD
were later shown to be positive. The patient initially had
The prevalence of HIV infection among hemodialysisincreased urinary protein excretion and renal dysfunc-
patients varies greatly with the geographic location oftion. On a treatment regimen consisting of corticoste-
the dialysis unit and patient demographics. Reportedroids, ACE inhibition, and four antiretroviral medica-
prevalence rates are likely underestimated due to lack
tions, the patient’s serum creatinine decreased to 1.7 of universal screening of hemodialysis patients for HIV
mg/dL 5 months following renal biopsy. The serum creat- infection. In the middle 1980s, it was suggested that HIV-
inine concentration remained less than 2 mg/dL until the infected hemodialysis patients suffered an extremely poor
patient was lost to follow-up 9 months after the renal prognosis and questions of whether it was ethical to offer
biopsy. Winston et al [20] reported similar results from chronic renal replacement therapy to these patients were
the use of HAART and short-term renal replacement debated [117]. Initial reports in the pre-HAART era
therapy in the setting of ARF in a patient with HIV-FGS. suggested a grave prognosis for patients with HIV infec-
The renal biopsy obtained upon clinical improvement tion and ESRD [117, 118]. However, data from the 1990s
demonstrated almost complete reversal of the initial glo- suggests improved survival, which, independent of treat-
merular and tubular damage. Interestingly, the authors, ment with HAART, may be related to improvements
through in situ hybridization, found HIV-1 RNA in both in dialytic techniques, anemia management, and other
factors [119–121]. In the United States, as of 1996, thetubular and glomerular epithelial cells [20] during treat-
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Fig. 2. Percentage of hemodialysis patients
with human immunodeficiency virus (HIV)
infection in the United States, 1985 to 2000.
Data used with permission from the Centers
for Disease Control and Prevention, Atlanta,
GA, USA and Seminars in Dialysis [122].
Fig. 3. Incidence of acquired immunodefi-
ciency syndrome (AIDS) nephropathy as a
primary diagnosis in end-stage renal disease
(ESRD) patients in the United States, 1990
to 1999. Data from the United States Renal
Data System [28].
Fig. 4. Incidence (%) of acquired immuno-
deficiency syndrome (AIDS) nephropathy as
a primary diagnosis in end-stage renal disease
(ESRD) patients in the United States, 1990
to 1999. Data from the United States Renal
Data System [28].
incidence of ESRD due to HIV-associated renal disease patients [121]. Furthermore, the stage of HIV infection
has, for the first time, declined (Figs. 2 to 4) [28, 122]. in peritoneal dialysis patients has been shown to be a
Furthermore, the incidence of HIV-associated ESRD primary determinant of survival [121, 125].
has stabilized in subsequent years, from an incidence of Recent work has focused on the effect of HAART on
810 patients in 1997 to 825 in 1999 (Figs. 3 and 4) [28]. patient survival in the HIV-infected ESRD population.
In a recent retrospective study [126] involving 22 HIV-
Renal replacement therapy infected patients who were started on maintenance he-
Evidence suggests that the most critical prognostic modialysis, Ahuja, Borucki, and Grady found a dramatic
factor in HIV-infected hemodialysis patients is the stage improvement in patient survival with the use of HAART
of viral infection. In a retrospective analysis, one study versus less aggressive therapy (one or two antiretroviral
showed that age, in addition to the presence and stage of medications). Of the patients not treated with HAART,
HIV infection, predicted survival in HIV-infected ESRD 57% died after a mean of 13 10 months on hemodialy-
patients [121]. In addition, the number of infections sus- sis, compared with only a 20% death rate at 28  17
tained by the patient per month and the urinary protein months on hemodialysis among the patients receiving
excretion (measured prior to the initiation of hemodialy- HAART. In this nonrandomized study, plasma viral load
sis) have been suggested as poor prognostic factors [123]. was significantly lower in the patients receiving HAART
A 1-year survival rate of 16% for dialysis patients with [126].
AIDS versus a 77% survival rate for HIV-infected pa-
Patient survival among the HIV-infected ESRD popu-tients without AIDS has been observed [120]. Dave,
lation may have improved with the addition of HAART.Shabih, and Blum [124], in a retrospective case review
However, published reports have yet to demonstrate aof 58 HIV-infected patients with ESRD, concluded that
profound effect on patient survival. With improvementsan initial CD4 cell count of50 cells/mm3 was a particu-
in detection of HIV-1 RNA viral burden, dialytic tech-larly poor prognostic marker. When associated with a
nique, and antiretroviral therapy, it is possible that HIV-serum albumin of 2.5g/dL, survival was reduced by a
infected patients with ESRD could survive for extendedmean of 8.3 months [124].
periods of time. On the contrary, it is possible that uremiaMean survival time for HIV-infected ESRD patients
and its associated immunosuppression may limit patientwas dramatically less when compared to uninfected pa-
prognosis. During hemodialysis, various cytokines, suchtients requiring renal replacement therapy in the middle
as IL-1, IL-6, and TNF-, are released [127–129]. These1990s [121]. Outcomes in patients treated with peritoneal
dialysis were equivalent when compared to hemodialysis cytokines have been shown to increase viral replication
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in vitro [130]. In the pre-HAART era, studies suggested Retroviruses and Opportunistic Infections, 2002, www.
that the degree of HIV viremia (using circulating levels emmes.com] shows similar results. Among 12 HIV-
of HIV p24 antigen as a surrogate for HIV viral load) infected patients who underwent renal transplantation,
in ESRD patients was similar to that in HIV-infected a 100% patient and graft survival was observed at 1 year.
patients with chronic renal insufficiency [131]. With this Recent data from the same group of investigators, re-
hypothesis in mind, Winston et al [abstract; Winston J garding 23 patients from eight transplant centers across
et al, J Am Soc Nephrol 7, 1345A, 1996] reported higher the United States, has been presented [abstract; Murphy
plasma viremia in HIV-infected patients undergoing he- B et al, J Am Soc Nephrol 13:11A, 2002]. Recruited pa-
modialysis compared with HIV-infected patients without tients had CD4 counts of200 cells/mm3 (mean baseline.
ESRD. In contrast to this finding, however, is the more 477 38 cells/mm3) and undetectable viral loads. Patients
recent study of Ahuja, Borucki, and Grady, in which were required to be on HAART for at least 6 months
almost 60% of surviving ESRD patients with HIV infec- prior to renal transplantation. There were 16 cadaveric
tion had undetectable viral loads at the time of study and seven living-related transplants. Acute rejection oc-
termination (range, 10 to 33 months) [126]. The relation- curred in 34.8% of patients. An 87% graft survival rate
ship between HAART, viral load, and patient prognosis was observed after a mean follow-up of 378  65.9 days.
in patients with renal disease is complex, and has yet to Follow-up viral loads were undetectable in 91% of pa-
be entirely explained. tients, with a mean CD4 count of 497  63 cells/mm3.
The calcineurin inhibitors, cyclosporin A (CsA) andTransplantation
FK506 (tacrolimus), have been shown to inhibit HIV-1
Most transplant units routinely screen potential organ DNA nuclear import and replication in vitro [132–136].
recipients for HIV infection. However, many have not Binding of HIV-1 p24 (gag) to cyclophilin A, the pre-
determined the appropriate treatment plan for seroposi- dominant cellular receptor protein of cyclosporins, is
tive patients. There are obvious concerns regarding im- required for HIV nuclear import [134, 135]. Cyclophilin
munosuppression and an adverse effect on the natural A also binds to nongag-encoded proteins, such as p17,
history of already immunosuppressed patients. Many Nef, Vif, and gp120 (env) [135]. Billich et al [135], using
transplant centers still regard HIV infection as an abso- a cyclosporin A analog (SDZ NIM 811), blocked the
lute contraindication to transplantation; however, sev- formation of the cyclophilin A-HIV-1 p24 gag complex.
eral centers in the United States are initiating clinical Recent evidence has focused on the role of CsA in
trials aimed at determining the effect of renal trans- inhibiting T-cell activation. The NFAT family of tran-
plantation and immunosuppressive medications on HIV-
scription factors has been suggested as a potential thera-infected patients [Roland M, www.emmes.com (personal
peutic target for the calcineurin inhibitors [132]. Croncommunication, 2002); Mannon R (personal communi-
et al [132] examined the role of NFAT1, the predominantcation, 2002); and Fung JJ (personal communication,
NFAT expressed in primary human peripheral CD4 T2002)].
cells, in HIV-1 transcription and p24 (gag) productionClinical experience from several transplant centers in
in vitro. Increasing NFAT1 and NFAT2 within primarythe United States suggests that renal transplantation and
human peripheral blood CD4 T cells infected with anits associated immunosuppressive regimens are feasible
HIV-1 provirus increased HIV-1 LTR transcription andin HIV-infected patients [abstract; Murphy B et al, J Am
p24 (gag) expression. Furthermore, the addition of eitherSoc Nephrol 13:11A, 2002].
CsA or FK506 inhibited such activity.Fung et al [Fung JJ: Clinical experience with HIV and
Recent evidence suggests that the addition of CsA totransplantation. The impact of highly active antiretrovi-
HAART may offer beneficial long-term effects to HIV-ral therapy (HAART) (presented at The American Soci-
infected patients. In an open-label, prospective studyety of Transplantation, 6th Annual Winter Symposium,
involving nine HIV-infected patients with an early stageLake Tahoe, CA, 2002)] described four HIV-infected
of infection (mean CD4 counts of 527  77 cells/L),patients who had undergone renal transplantation. Their
CsA was used during the first 8 weeks of treatment withpatients did not progress to AIDS (CD4200 cells/mm3)
HAART (stavudine, lamivudine, nelfinavir, and saqui-and maintained undetectable viral loads (less than 50
navir). This regimen resulted in a rapid restoration ofcopies/mL) at 1, 1, 2, and 3 years following transplanta-
CD4 T cells in the absence of a simultaneous increasetion. Three patients were weaned off corticosteroids and
in total T-cell production (within 7 days) [137]. The long-maintained serum creatinine concentrations of 1.2 to 1.6
term effect of calcineurin inhibitors on patient survival,mg/dL. One patient had “moderate to severe” rejection
HIV-1 viral replication, and disease progression is notwith a functioning graft (serum creatinine concentration
known, and remains to be studied in randomized con-2.5 to 3 mg/dL). All four patients were alive at 1, 1, 2,
trolled trials in patients with renal disease.and 3 years, respectively. A prospective study conducted
Mycophenolate mofetil, a commonly used immuno-by centers in San Francisco and Philadelphia [Roland
M et al, in a presentation at the 9th Conference on suppressive medication, has been evaluated for its activ-
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